NEW YORK, April 18, 2016 /PRNewswire/ -- BeyondSpring Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, including a Phase III immuno-oncology compound and strong pipeline in collaboration with the Fred Hutchinson Cancer Research Center, today announced that Chief Medical Officer Ramon Mohanlal, M.D., Ph.D., presented the Company's planned Phase III trial of Plinabulin in Docetaxel-induced Neutropenia at the BIO Spring meeting on April 4 through 6, 2016, in Stockholm, Sweden.
"A significant observation in our Phase II clinical trial was that Plinabulin mitigated Docetaxel-induced grade 4 Neutropenia and its clinical sequelae (severe infections, sepsis, hospitalizations), improving Docetaxel dose intensity," said Dr. Mohanlal. "Thus, Plinabulin's product profile is very attractive, as it can become an effective, safe, convenient and cost-effective alternative to G-CSF, including its biosimilars."
While at the conference, Dr. Mohanlal also had partnering meetings with major pharmaceutical companies regarding BeyondSpring's Neutropenia program with Plinabulin.
Neutropenia is the reduction of white blood cells that are key components of the immune system and frequently results from treatment with chemotherapy. Patients with Neutropenia are more susceptible to bacterial infections, and this condition (Febrile Neutropenia) carries a high risk for mortality and often requires hospitalization.
About BeyondSpring Pharmaceuticals
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative cancer therapies targeting immuno-oncology and tumor vascularization. BeyondSpring has advanced its lead asset, Plinabulin, into a Phase III clinical trial as a direct anticancer agent in non-small cell lung cancer. The Company is also planning a Phase III clinical trial for Plinabulin in the prevention of Docetaxel-induced Neutropenia. BeyondSpring's management team brought a combined 30+ drugs to market. The Company's immuno-oncology pipeline is robust, including a collaboration agreement with the Fred Hutchinson Cancer Research Center.
Plinabulin is a small molecule agent that is administered by IV infusion (30-minute infusion) and is administered 60 minutes after completion of Docetaxel infusion, on the same day of Docetaxel infusion.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/beyondspring-cmo-presented-at-bio-spring-2016-300253058.html
SOURCE BeyondSpring Pharmaceuticals